Roche Finalizes Poseida Acquisition: This Cell Therapy Deal Feels Like A Win/Win
Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.
Zacks.com on MSN9h
HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up
Shares of Halozyme Therapeutics, Inc. HALO were up 5% on Jan. 8 after the company raised its guidance for 2025. The stock gained another 1.8% in after-hours trading. HALO also maintained its full-year ...
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...
Hosted on MSN11h
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across ...